[1] DOMINGUES I, LECLERCQ I A, BELOQUI A. Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery[J]. J Control Release, 2023, 363: 415-434. [2] DATZ C, MüLLER E, AIGNER E. Iron overload and non-alcoholic fatty liver disease[J]. Minerva Endocrinol, 2017, 42(2): 173-183. [3] BRITTON L, BRIDLE K, REILING J, et al. Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease[J]. Hepatol Commun, 2018, 2(6): 644-653. [4] GAO H, JIN Z M, BANDYOPADHYAY G, et al. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis[J]. Cell Metab, 2022, 34(8): 1201-1213.e5. [5] KARKUCINSKA-WIECKOWSKA A, SIMOES I C M, KALINOWSKI P, et al. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: a complex relationship[J]. Eur J Clin Invest, 2022, 52(3): e13622. [6] CHEN Z, TIAN R F, SHE Z G, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J]. Free Radic Biol Med, 2020, 152: 116-141. [7] WU D D, LIU Z G, WANG Y Z, et al. Epigallocatechin-3-gallate alleviates high-fat diet-induced nonalcoholic fatty liver disease via inhibition of apoptosis and promotion of autophagy through the ROS/MAPK signaling pathway[J]. Oxid Med Cell Longev, 2021, 2021: 597. [8] YAMADA T, MURATA D, ADACHI Y, et al. Mitochondrial stasis reveals p62-mediated ubiquitination in parkin-independent mitophagy and mitigates nonalcoholic fatty liver disease[J]. Cell Metab, 2018, 28(4): 588-604.e5. [9] HASHEM A, KHALOUF A, ACOSTA A. Management of obesity and nonalcoholic fatty liver disease: a literature review[J]. Semin Liver Dis, 2021, 41(4): 435-447. [10] ZHANG L J, DAI X Z, WANG L, et al. Iron overload accelerated lipid metabolism disorder and liver injury in rats with non-alcoholic fatty liver disease[J]. Front Nutr, 2022, 9: 961892. [11] QIU Y Y, ZHANG J, ZENG F Y, et al. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)[J]. Pharmacol Res, 2023, 192: 106786. [12] TWIG G, ELORZA A, MOLINA A J A, et al. Fission and selective fusi on govern mitochondrial segregation and elimination by autophagy[J]. EMBO J, 2008, 27(2): 433-446. [13] 潘琳琳, 相宏杰, 刘桂荣. 理脾降浊方通过调控HIF-1α/PPARγ/BNIP3线粒体自噬途径改善小鼠非酒精性脂肪肝的机制研究[J]. 时珍国医国药, 2024, 35(8): 1862-1867. [14] ZHOU T, CHANG L, LUO Y, et al. Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing Parkin-related mitophagy[J]. Redox Biol, 2019, 21: 101120. [15] LEE D H, JUNG Y Y, PARK M H, et al. Peroxiredoxin 6 confers protection against nonalcoholic fatty liver disease through maintaining mitochondrial function[J]. Antioxid Redox Signal, 2019, 31(5): 387-402. |